display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
locally advanced NSCLC - (neo)adjuvant (NA)locally advanced NSCLC - maintenance (M)metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)NSCLC neoadjuvant setting
locally advanced NSCLC - (neo)adjuvant (NA)laNSCLC - M - all populationmNSCLC - L1 - all populationmNSCLC - L1 - PDL1 negativemNSCLC - L1 - PDL1 positivenon squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)squamous - mNSCLC - L1 - all populationmNSCLC - L2 - all populationmNSCLC - L2 - EGFR mutantmNSCLC - L2 - PDL1 positivenon squamous - mNSCLC - L2 - all populationsquamous - mNSCLC - L2 - all populationNSCLC neoadjuvant setting
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMpower-110 ... IMpower-110 ... IMpower-110 ... OAK ... POPLAR OAK ...
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel IMpower-150 ... IMpower-150 ... IMpower-150 ...
atezolizumab plus carboplatin plus nab-paclitaxel IMpower-130 ... IMpower-130 ... IMpower-131 ...
atezolizumab plus carboplatin plus paclitaxel IMpower-150 ... IMpower-131 ...
atezolizumab plus pemetrexed and platin IMpower-132 ...
avelumab based treatment
avelumab alone JAVELIN Lung 200 ... JAVELIN Lung 200 ...
cemiplimab EMPOWER lung1 ... EMPOWER lung1 ...
durvalumab based treatment
durvalumab alone PACIFIC MYSTIC ... MYSTIC ... ARCTIC ...
durvalumab plus osimertinib CAURAL ...
nivolumab based treatment
nivolumab alone CheckMate 026 ... CheckMate 026 ... CheckMate 078 CheckMate 057 CheckMate 017
nivolumab plus SoC CheckMate 816 CheckMate 227 ... CheckMate 816
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-042 ... KEYNOTE-042 ... KEYNOTE-042 ... KEYNOTE-024 ...
pembrolizumab (10mg/kg) KEYNOTE-010 ... KEYNOTE-010 ...
pembrolizumab (2mg/kg) KEYNOTE-010 ... KEYNOTE-010 ...
pembrolizumab and pemetrexed plus platin KEYNOTE-021
pembrolizumab plus SoC KEYNOTE-189 KEYNOTE-407
sintilimab based treatment
sintillimab plus SoC ORIENT-11
Tislelizumab RATIONALE 303

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons